Dabomb Protein Biotech Corporation AI Stock Analysis
Dabomb Protein Biotech Corporation (6578) AI Stock Analysis
Dabomb Protein Biotech Corporation
(TPEx:6578)
Dabomb Protein Biotech scores low primarily because of deteriorating operating fundamentals: six straight years of revenue decline, a swing back to a NT$69 million net loss, and negative free cash flow leave the business operationally challenged. This is only partially offset by an exceptionally strong, nearly debt-free balance sheet (debt-to-equity of 0.08) and recovering gross margins, which reduce near-term solvency risk and buy time for a turnaround. Technicals are neutral-to-soft, with the price below its 50-, 100- and 200-day averages and momentum indicators mid-range. Valuation provides little support given negative earnings, though a 2.37% dividend yield adds modest income appeal. The key watch item is whether revenue can stabilize and margin gains can finally translate into sustained profitability.
Dabomb Protein Biotech Corporation (6578) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.21B
- Dividend Yield
- 2.37%
- Average Volume (3M)
- 56.84K
- Price to Earnings (P/E)
- -51.7
- Beta (1Y)
- 0.06
- Revenue Growth
- 21.50%
- EPS Growth
- -5.51%
- Country
- TW
- Employees
- 46
- Sector
- General
- Sector Strength
- 55
- Industry
- Packaged Foods
Dabomb Protein Biotech Corporation Business Overview & Revenue Model
Company Description
DaBomb Protein Biotech Corp. is a specialized biotechnology enterprise primarily dedicated to developing and commercializing antibiotic replacements for the animal health industry. Its extensive product range includes plant-based proteins such as DaB...
Dabomb Protein Biotech Corporation Financial Statement Overview
Summary
A very weak earnings profile (score 24) dominates: revenue has declined six consecutive years to NT$309 million, including a 24.9% drop in the latest year, and 2025 brought a return to an operating loss of NT$28 million and a net loss of NT$69 million (-22.4% net margin). Cash generation is thin (score 35) — operating cash flow fell to NT$17 million and free cash flow turned negative again at -NT$21 million, the fifth negative year out of six. The clear offset is a fortress-like balance sheet (score 70): borrowings cut from NT$618 million to NT$74 million, debt-to-equity of just 0.08, and equity funding roughly 90% of assets, which sharply limits solvency risk. Improving gross margins (4.5% to 22.3%) are an encouraging early signal, but the equity base is eroding and ROE remains negative at -7.0%.
Income Statement
24NegativeBalance Sheet
70PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 339.44M | 309.33M | 337.82M | 384.41M | 433.63M | 470.63M |
| Gross Profit | 56.07M | 69.03M | 68.73M | 46.43M | 19.33M | 21.65M |
| EBITDA | 35.71M | -22.25M | 34.98M | -26.00M | -15.49M | -40.80M |
| Net Income | -41.91M | -69.34M | 11.64M | -57.02M | -44.66M | -62.45M |
Balance Sheet | ||||||
| Total Assets | 1.12B | 1.10B | 1.32B | 1.40B | 1.28B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 168.72M | 160.63M | 304.98M | 429.45M | 232.01M | 266.87M |
| Total Debt | 68.49M | 74.21M | 168.53M | 418.00M | 496.04M | 618.30M |
| Total Liabilities | 111.38M | 106.48M | 225.96M | 443.83M | 552.88M | 662.24M |
| Stockholders Equity | 1.01B | 989.28M | 1.09B | 958.06M | 727.20M | 674.24M |
Cash Flow | ||||||
| Free Cash Flow | 25.34M | -21.04M | 17.23M | -12.37M | -449.00K | -376.35M |
| Operating Cash Flow | 40.36M | 16.65M | 47.55M | 6.51M | 19.71M | -44.25M |
| Investing Cash Flow | -16.32M | -14.42M | -31.48M | -31.89M | 12.96M | -382.75M |
| Financing Cash Flow | -97.52M | -122.84M | -139.75M | 208.85M | -34.15M | 356.71M |
Dabomb Protein Biotech Corporation Peers Comparison
Overall Rating
TW:684655Neutral
TW:413348Neutral- TW:657842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6846 | 55Neutral | TWD 1.33B | 12.56 | ― | 8.05% | -3.09% | -27.22% |
| TW:4133 | 48Neutral | TWD 1.20B | 27.03 | ― | 0.56% | -4.19% | ― |
| TW:6578 | 42Neutral | TWD 1.21B | -51.66 | ― | 2.37% | 21.50% | -5.51% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6578 | Dabomb Protein Biotech Corporation | 17.00 | -2.70 | -13.71% | |
| TW:4133 | Abnova Taiwan Corp. | 20.00 | -3.27 | -14.07% | |
| TW:6827 | MegaPro Biomedical Co., Ltd. | 15.30 | -0.15 | -0.97% | |
| TW:6846 | Greenyn Biotechnology Co., Ltd. | 49.00 | -24.13 | -32.99% | |
| TW:6886 | Far East Bio-Tec. Co., Ltd. | 36.70 | -4.66 | -11.27% | |
| TW:7814 | Horien Biochemical Technology Co., Ltd. | 27.30 | -13.00 | -32.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026